loading
前日終値:
$6.61
開ける:
$6.63
24時間の取引高:
1.85M
Relative Volume:
1.41
時価総額:
$752.55M
収益:
-
当期純損益:
$-242.30M
株価収益率:
-2.6129
EPS:
-2.48
ネットキャッシュフロー:
$-192.10M
1週間 パフォーマンス:
-9.50%
1か月 パフォーマンス:
-7.30%
6か月 パフォーマンス:
-40.55%
1年 パフォーマンス:
-3.57%
1日の値動き範囲:
Value
$6.31
$6.69
1週間の範囲:
Value
$6.31
$7.49
52週間の値動き範囲:
Value
$5.88
$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name
名前
Cogent Biosciences Inc
Name
セクター
Healthcare (1166)
Name
電話
617-945-5576
Name
住所
275 WYMAN STREET, WALTHAM
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
COGT's Discussions on Twitter

COGT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
COGT
Cogent Biosciences Inc
6.48 752.55M 0 -242.30M -192.10M -2.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-07 開始されました Scotiabank Sector Outperform
2024-12-11 ダウングレード Needham Buy → Hold
2024-02-26 ダウングレード Robert W. Baird Outperform → Neutral
2024-02-08 開始されました Citigroup Buy
2023-12-11 ダウングレード Wedbush Outperform → Neutral
2023-12-08 開始されました JP Morgan Overweight
2023-04-28 開始されました Robert W. Baird Outperform
2023-03-27 再開されました H.C. Wainwright Buy
2022-12-14 開始されました Needham Buy
2022-06-28 開始されました Guggenheim Buy
2021-10-11 開始されました H.C. Wainwright Buy
2021-06-09 再開されました Jefferies Buy
2020-12-23 開始されました Piper Sandler Overweight
2020-10-14 開始されました Ladenburg Thalmann Buy
すべてを表示

Cogent Biosciences Inc (COGT) 最新ニュース

pulisher
10:04 AM

We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance UK

10:04 AM
pulisher
04:15 AM

Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

04:15 AM
pulisher
Mar 26, 2025

Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire

Mar 26, 2025
pulisher
Mar 25, 2025

Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan

Mar 25, 2025
pulisher
Mar 25, 2025

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - Nasdaq

Mar 20, 2025
pulisher
Mar 18, 2025

Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Insider Monkey

Mar 17, 2025
pulisher
Mar 14, 2025

Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter

Mar 10, 2025
pulisher
Mar 09, 2025

Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 08, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

When the Price of (COGT) Talks, People Listen - Stock Traders Daily

Mar 03, 2025
pulisher
Feb 28, 2025

Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating - TipRanks

Feb 26, 2025
pulisher
Feb 25, 2025

Cogent Biosciences (COGT) Surprises Wall Street with Narrower-Than-Expected Q4 Loss - HPBL

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences (COGT) Reports Q4 2024 Net Loss of $67.9 Mill - GuruFocus.com

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences, Inc. SEC 10-K Report - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can Cogent's Triple Catalyst Year Transform Rare Disease Treatment? 3 Key Trial Results Coming in 2025 - StockTitan

Feb 25, 2025
pulisher
Feb 22, 2025

Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 21, 2025

Long Term Trading Analysis for (COGT) - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 14, 2025

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News

Feb 13, 2025
pulisher
Feb 11, 2025

Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

FY2025 Earnings Estimate for COGT Issued By Leerink Partnrs - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.33 Consensus PT from Brokerages - Defense World

Feb 11, 2025

Cogent Biosciences Inc (COGT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):